Home › NCT03681275

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

A Clinical Trial of JAK Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients undergoing esophagectomy

Exclusion Criteria:

* Patients with more than mild pulmonary dysfunction
* Patients with any neuromuscular disease that might compromise diaphragm function
* Patients with abnormal liver or kidney function
* Patients taking any immunosuppressant medication (including prednisone) or antifungal medications
* History of tuberculosis
* Weight loss of \>5% of body weight over previous 6 months
* Pregnancy

About the study

We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD.

What is being tested

• Tofacitinib 10 MG [Xeljanz] (drug)
• Placebo to match Tofacitinib (drug)

Sponsor: Stanford University · Participants: 70 · Started: Sep 3, 2019

Contact the study team

• Cheyenne A Clinical Research Coordinator, B.S, M.S · Phone: 3107201689

Official record on ClinicalTrials.gov — NCT03681275

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.